Search Articles — Sudonull

Search Results

In this project

Forecasting power line accidents using auroras: RAS method

https://sudonull.com/forecasting-power-line-accidents-using-auroras-ras-method

Scientists from the Geophysical Center of the Russian Academy of Sciences have developed a method for assessing geomagnetically induced currents using auroras. Accident probability is 7.5%. Learn about risks for the Arctic.

From other projects

AI test for bladder cancer: FDA breakthrough device

https://ymaho.com/ai-test-for-bladder-cancer-fda-breakthrough-device

FDA has granted breakthrough device designation to an AI tool for predicting bladder cancer prognosis. Learn how Vesta by Valar Labs is changing oncourology and treatment economics.

Tzield approved for children from 1 year: delaying type 1 diabetes

https://ymaho.com/tzield-approved-for-children-from-1-year-delaying-type-1-diabetes

FDA expanded indications for teplizumab to children from one year. First drug capable of delaying diabetes for years at the preclinical stage. Learn how infusions change the prognosis for infants.

Hantavirus outbreak on a cruise ship: WHO analysis and risks

https://ymaho.com/hantavirus-outbreak-on-a-cruise-ship-who-analysis-and-risks

WHO reported an outbreak of hantavirus ANDV on the MV Hondius ship with 7 cases and 3 deaths. Learn about the timeline, transmission risks, and prognosis. Read the full analysis.

Bulevirtide (Hepcludex®): FDA approval for hepatitis D

https://ymaho.com/bulevirtide-hepcludex-fda-approval-for-hepatitis-d

FDA approved the first drug for chronic hepatitis D — bulevirtide. Mechanism, doses, risks, price, and prognosis. Find out who is suitable for therapy.

Gene therapy AB-1009 for Pompe disease: clinical trial

https://ymaho.com/gene-therapy-ab-1009-for-pompe-disease-clinical-trial

A clinical trial of gene therapy AB-1009 for late-onset Pompe disease (LOPD) has begun. Phase 1 analysis, mechanism of action, risks, and prognosis. Learn more.

Targeted therapy for Usher syndrome 1B: new data on AAVB-081

https://ymaho.com/targeted-therapy-for-usher-syndrome-1b-new-data-on-aavb-081

Interim data from phase 1/2 gene therapy AAVB-081 for Usher syndrome 1B: safety, efficacy, and prognosis. Learn about the dual AAV vector and treatment prospects.

Trending Now